Gilead Ceo Daniel O'day On Remdesivir Pricing And Ensuring Access To Treatment

Gilead CEO Daniel O'Day on remdesivir pricing and ensuring access to treatment

CNBC Television

Gilead sets U.S. price for Covid-19 drug remdesivir at $3,120 for typical treatment

CNBC Television

Daniel O’Day of Gilead Sciences, Inc. on COVID-19 Efforts

Gilead CEO on promising study results for remdesivir Covid-19 treatment

CNBC Television

Gilead: Additional remdesivir data shows improved recovery

CNBC Television

Gilead CEO on treating Covid-19: 'We're not finished with remdesivir'

CNBC Television

President Trump & Gilead CEO Daniel O'Day on emergency FDA approval of Remdesivir

Gilead CEO Daniel O'Day on acquisition of cancer drugmaker Immunomedics

CNBC Television

FDA approves Gilead's Remdesivir as a coronavirus treatment

CNBC Television

Gilead CEO Dan O'Day offers a detailed explanation on remdesivir access Covid-19 treatment

Gilead's moving quickly with FDA for approval of coronavirus drug remdesivir: CEO

CNBC Television

Gilead CEO: Oral version of Covid drug Remdesivir in early testing

CNBC Television

Gilead Sciences CEO Daniel O'Day Remarks at 2019 World AIDS Day Observances

National AIDS Memorial

Remdesivir Company CEO: It’s ‘Not A Cure, But A Very Significant Treatment’ | TODAY

Gilead to charge thousands for coronavirus treatment drug that critics say should cost $1

EU Debates | eudebates.tv

Gilead CEO: We can manufacture enough remdesivir to provide all of the U.S.

CNBC Television

Remdesivir to arrive at hospitals this week, Gilead CEO says

Why this Raymond James analyst calls for a clinical reassessment of Gilead's remedsivir treatment

CNBC Television

Pres. Donald Trump, FDA, Gilead CEO discuss the emergency authorization for Remdesivir

CNBC Television

Gilead's Remdesivir treatment could see recurring revenue even if a Covid-19 vaccine is found: Jeffe

CNBC International News